本研究旨在评估碳离子放射治疗（CIRT）治疗脉络膜恶性黑色素瘤（CMM）的长期结果，特别是在保护眼睛和视力（VA）方面。总共250名眼内局限性CMM患者接受了碳离子放射治疗2003 年 1 月至 2021 年 9 月期间的 CIRT 也包含在内。剂量处方包括 60-85 Gy/4-5 fr，从 2018 年起仅使用 68 Gy/4 fr。带扫描光束的旋转龙门系统于 2018 年 4 月推出。不良事件 (AE) 根据 AE 通用术语标准（5.0 版）进行分级。对于继发性青光眼，与肿瘤相关的视野缺陷被排除在评估之外。对于 VA，对 245 名 VA≥光感 (LP) 的患者进行了随访。以有效VA（EV：≥20/200，Snellen等效）、计数手指（CF）和LP为指标。中位年龄为55（15-86）岁。分别有 16 名 (6.4%)、41 名 (16.4%)、189 名 (75.6%) 和 4 名 (1.6%) 患者出现 T 类别 1、2、3 和 4。中位随访时间为72.5个月，5年和8年总生存率分别为87.5%和84.2%； 5年和8年局部控制率分别为94.4%和92.9%。在最后一次随访时，250 名患者中有 19 名（7.6%）接受了摘除术，其中 15 名因局部复发，4 名因 AE。继发性青光眼 1 级、2 级和 3-4 级分别有 22 名（8.8%）、49 名（19.6%）和 5 名患者（2.0%）观察到。在最后一次随访时，分别有 80 名（33%）、120 名（49%）和 154 名（63%）患者维持≥ EV、≥ CF 和 ≥ LP。 CIRT 后 5 年和 8 年≥LP 视力的保留率分别为 65.7% 和 55.3%。CMM 的 CIRT 是一种有前途的治疗方法，用于控制肿瘤和保护眼睛和 VA。版权所有 © 2024。由 Elsevier Inc. 出版。

This study aimed to evaluate the long-term results of carbon ion radiotherapy (CIRT) for choroidal malignant melanoma (CMM), especially regarding the preservation of the eye and visual acuity (VA).A total of 250 patients with intraocularly localized CMM treated with CIRT between January 2003 and September 2021 were included. The dose prescription included 60-85 Gy/4-5 fr, with only 68 Gy/4 fr used from 2018 onwards. The rotating gantry system with scanning beams was introduced in April 2018. Adverse events (AEs) were graded according to the Common Terminology Criteria for AEs (version 5.0.) For secondary glaucoma, tumor-related visual field defects were excluded from the evaluation. For VA, 245 patients with VA≥ light perception (LP) were followed up. Effective VA (EV: ≥ 20/200, Snellen equivalent), counting fingers (CF) and LP were used as indicators.The median age was 55 (15-86) years. The T- categories 1, 2, 3, and 4 were observed in 16 (6.4%), 41 (16.4%), 189 (75.6%), and 4 (1.6%) patients, respectively. With a median follow-up of 72.5 months, the 5- and 8-year overall survival rates were 87.5% and 84.2%, respectively; the 5- and 8-year local control rates were 94.4% and 92.9%, respectively. At the last follow-up, 19 of 250 patients (7.6%) underwent enucleation, 15 due to local recurrence and 4 due to AEs. Secondary glaucoma grades 1, 2, and 3-4 were observed in 22 (8.8%), 49 (19.6%), and 5 patients (2.0%), respectively. At the last follow-up, ≥ EV, ≥ CF, and ≥ LP were maintained in 80 (33%), 120 (49%), and 154 (63%) patients, respectively. Preservation rate of ≥LP vision at 5 and 8 years after CIRT was 65.7% and 55.3%, respectively.CIRT for CMM is a promising treatment for both tumor control and preservation of the eye and VA.Copyright © 2024. Published by Elsevier Inc.